Published in Lab Business Week, September 26th, 2004
Revenues of $8.0M grew by 8% from the prior period (2003 $7.4M). This was primarily due to increased profit share revenues from diagnostic sales by Thermo Electron of $3.5M, up 117% from 2003.
Profit share was generated by sales of the FLU OIA diagnostic product, as well as a new FLU OIA A/B diagnostic recently added to the range, and was boosted by the influenza epidemic in the USA during the northern hemisphere winter.
Relenza royalties of $0.6M fell by almost 50% from the prior period payment (2003 $1.1M), due to the ongoing decline...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week